|
|
Volumn 19, Issue 22, 2011, Pages 6726-6734
|
|
Design, synthesis and biological evaluation of 3-substituted 2,5-dimethyl-N-(3-(1H-tetrazol-5-yl)phenyl)pyrroles as novel potential HIV-1 gp41 inhibitors
a
b
c
a
b,d
c
a
|
|
Author keywords
3 Substituted 2,5 dimethyl N (3 tetrazol 5 yl)phenyl)pyrrole derivatives; Anti HIV agents; HIV 1 gp41; Small molecule fusion inhibitors
|
|
Indexed keywords
2,5 DIMETHYL 3 [5 (N PHENYLRHODANINYL)METHYLENE] N [3 (1H TETRAZOL 5 YL)PHENYL]PYRROLE;
3 (3 BROMOPHENYL) 5 [[1 [3 (1H TETRAZOL 5 YL)PHENYL] 2,5 DIMETHYL 1H PYRROL 3 YL]METHYLENE] 2 THIOXOTHIAZOLIDIN 4 ONE;
3 (3 HYDROXYPHENYL) 5 [[1 [3 (1H TETRAZOL 5 YL)PHENYL] 2,5 DIMETHYL 1H PYRROL 3 YL]METHYLENE] 2 THIOXOTHIAZOLIDIN 4 ONE;
3 (3 METHOXYPHENYL) 5 [[1 [3 (1H TETRAZOL 5 YL)PHENYL] 2,5 DIMETHYL 1H PYRROL 3 YL]METHYLENE] 2 THIOXOTHIAZOLIDIN 4 ONE;
3 (3 NITROPHENYL) 5 [[1 [3 (1H TETRAZOL 5 YL)PHENYL] 2,5 DIMETHYL 1H PYRROL 3 YL]METHYLENE] 2 THIOXOTHIAZOLIDIN 4 ONE;
3 (4 BROMOPHENYL) 5 [[1 [3 (1H TETRAZOL 5 YL)PHENYL] 2,5 DIMETHYL 1H PYRROL 3 YL]METHYLENE] 2 THIOXOTHIAZOLIDIN 4 ONE;
3 (4 HYDROXYPHENYL) 5 [[1 [3 (1H TETRAZOL 5 YL)PHENYL] 2,5 DIMETHYL 1H PYRROL 3 YL]METHYLENE] 2 THIOXOTHIAZOLIDIN 4 ONE;
3 (4 METHOXYPHENYL) 5 [[1 [3 (1H TETRAZOL 5 YL)PHENYL] 2,5 DIMETHYL 1H PYRROL 3 YL]METHYLENE] 2 THIOXOTHIAZOLIDIN 4 ONE;
3 (4 METHOXYPHENYL) 5 [[1 [3 (1H TETRAZOL 5 YL)PHENYL] 2,5 DIMETHYL 1H PYRROL 3 YL]METHYLENE]IMIDAZOLIDINE 2,4 DIONE;
3 (PHENYLETHYL) 5 [[1 [3 (1H TETRAZOL 5 YL)PHENYL] 2,5 DIMETHYL 1H PYRROL 3 YL]METHYLENE] 2 THIOXOTHIAZOLIDIN 4 ONE;
3 [3 (TRIFLUOROMETHYL)PHENYL] 5 [[1 [3 (1H TETRAZOL 5 YL)PHENYL] 2,5 DIMETHYL 1H PYRROL 3 YL]METHYLENE] 2 THIOXOTHIAZOLIDIN 4 ONE;
3 [3 (TRIFLUOROMETHYL)PHENYL] 5 [[1 [3 (1H TETRAZOL 5 YL)PHENYL] 2,5 DIMETHYL 1H PYRROL 3 YL]METHYLENE]IMIDAZOLIDINE 2,4 DIONE;
3 [4 (TRIFLUOROMETHYL)PHENYL] 5 [[1 [3 (1H TETRAZOL 5 YL)PHENYL] 2,5 DIMETHYL 1H PYRROL 3 YL]METHYLENE] 2 THIOXOTHIAZOLIDIN 4 ONE;
3 BENZYL 5 [[1 [3 (1H TETRAZOL 5 YL)PHENYL] 2,5 DIMETHYL 1H PYRROL 3 YL]METHYLENE] 2 THIOXOTHIAZOLIDIN 4 ONE;
3 PHENYL 5 [[1 [3 (1H TETRAZOL 5 YL)PHENYL] 2,5 DIMETHYL 1H PYRROL 3 YL]METHYLENE] 2 THIOXOTHIAZOLIDIN 4 ONE;
5 [3 [3 (2 CYANO 2 ETHOXYCARBOXYLVINYL) 2,5 DIMETHYL 1H PYRROL 1 YL]PHENYL] 1H TETRAZOLE;
5 [3 [3 (2 NITROVINYL) 2,5 DIMETHYL 1H PYRROL 1 YL]PHENYL] 1H TETRAZOLE;
5 [3 [3 (2,2 DICYANOVINYL) 2,5 DIMETHYL 1H PYRROL 1 YL]PHENYL] 1H TETRAZOLE;
5 [3 [3 (2,2 DIETHOXYCARBOXYLVINYL) 2,5 DIMETHYL 1H PYRROL 1 YL]PHENYL] 1H TETRAZOLE;
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
GLYCOPROTEIN GP 41;
N [3 (1H TETRAZOL 5 YL)PHENYL] 2,5 DIMETHYLPYRROLE;
NB 64;
UNCLASSIFIED DRUG;
ANTIVIRAL ACTIVITY;
CONFERENCE PAPER;
CONTROLLED STUDY;
DRUG DESIGN;
DRUG POTENCY;
DRUG SCREENING;
DRUG STRUCTURE;
DRUG SYNTHESIS;
DRUG TARGETING;
HUMAN;
HUMAN CELL;
HUMAN IMMUNODEFICIENCY VIRUS 1;
IC 50;
NONHUMAN;
VIRUS REPLICATION;
ANTI-HIV AGENTS;
BINDING SITES;
HIV ENVELOPE PROTEIN GP41;
HIV-1;
HUMANS;
PYRROLES;
STRUCTURE-ACTIVITY RELATIONSHIP;
TETRAZOLES;
HUMAN IMMUNODEFICIENCY VIRUS 1;
|
|
EID: 80054980514
PISSN: 09680896
EISSN: 14643391
Source Type: Journal
DOI: 10.1016/j.bmc.2011.09.047 Document Type: Conference Paper |
|
Times cited : (61)
|
|
References (29)
|
